Genzyme files patent infringement suit against DRL
Updated: Sep 23 2013, 08:27am hrs
Genzyme, a fully-owned subsidiary of drug major Sanofi, has filed a suit against Dr Reddys Laboratories alleging that the Indian drug maker infringed patents of its cancer drug Mozobil on three counts. Mozobil (plerixafor injection) is a haematopoietic stem cell mobiliser indicated to patients with non-Hodgkins lymphoma (blood cancer) and multiple myeloma. In its petition filed in the District Court of Delaware, Genzyme alleged that DRL intimated though a letter that it had submitted an Abbreviated New Drug Application with the USFDA seeking a nod to engage in the commercial manufacture, import, use and sale of 20 mg/ml Plerixafor injection as a generic version of Mobozil.